BI 201335: Additional Phase IIb data

Additional data from the open-label Phase IIb SOUND-C2 trial in 362 treatment-naïve patients with chronic HCV genotype 1 infection showed that 61% of patients receiving once-daily 120 mg BI 201335 plus thrice-daily 600 mg BI 207127 and ribavirin for 28 weeks achieved an SVR 12 weeks after the end of treatment. Additionally, 68% of patients receiving once-daily 120 mg BI 201335 plus twice-daily 600 mg BI 207127 and ribavirin for 28 weeks achieved an SVR12, while 39% of patients receiving once-daily 120 mg BI 201335 plus thrice-daily 600 mg BI 207127 without ribavirin for 28 weeks achieved an SVR12. Data were presented at the European Association for the Study of the Liver meeting in Barcelona. ...